Silo Pharma (NASDAQ: SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the company’s common stock. The program allows purchases on the open market, through privately negotiated transactions, or otherwise, in compliance with SEC rules and applicable legal requirements. As of Nov. 13, 2025, the company reported 13,318,273 shares of common stock outstanding, according to its quarterly report for the period ended Sept. 30, 2025.
The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations. The program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion. This move often indicates that management believes the stock is undervalued and can help support the share price by reducing the number of shares outstanding.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
For more details, the full press release is available at https://ibn.fm/gU3uZ. The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO.
The repurchase program underscores Silo Pharma's commitment to enhancing shareholder value while continuing its focus on developing treatments for conditions with high unmet medical needs. As a developmental-stage company, the repurchase authorization provides flexibility to manage capital allocation in a way that benefits long-term investors.
